Patients with psoriatic arthritis (PsA) may have an increased prevalence, burden and severity of coronary atherosclerosis as measured by coronary CT angiography (CCTA), a recent study suggests.
Keeping a dog or a cat can help lower the likelihood of hypertension and elevated blood pressure (BP) in children, according to a recent study that investigated the association between pet exposure and BP in children.
Corn oil intake appears to substantially reduce atherogenic lipoprotein cholesterol and particle concentrations compared with extra-virgin olive oil (EVOO), a study has shown.
The use of certain systemic medications may influence intraocular pressure (IOP), and potentially, glaucoma risk, according to a post hoc analysis of the SEED* study.
Individuals with unrecognized myocardial infarction (MI) were less sensitive to pain compared with those who experience recognized MI, suggesting that differences in pain tolerance may affect the perception of MI, according to the Tromsø Study.
The standard-dose combination of calcium channel blocker (CCB) plus angiotensin receptor blocker (ARB) appears to provide better blood pressure (BP)-lowering benefits in hypertensive patients compared with high-dose CCB monotherapy, with the added advantage of lower adverse event rate, according to the results of a meta-analysis.
Extended-duration thromboprophylaxis with betrixaban, a factor Xa inhibitor, significantly reduces the risk of stroke in hospitalized acutely ill patients, according to a multinational group of researchers.
Direct oral anticoagulants (DOACs) may be associated with a lower risk of liver injury hospitalization relative to warfarin, with dabigatran having the lowest risk, a recent study has shown.
Lupus myocarditis (LM) is a severe symptom of systemic lupus erythematosus (SLE), according to a new study, adding that LM can be the first indication of the disease or can occur during follow-up, particularly in untreated patients.
Cangrelor shows efficacy in reducing ischaemic complication in patients undergoing percutaneous coronary intervention (PCI) with or without glycoprotein IIb/IIIa inhibitors (GPIs), according to a pooled, patient-level analysis of the three CHAMPION* trials.